Bicara Therapeutics (BCAX) Competitors $20.43 +0.40 (+2.00%) Closing price 04:00 PM EasternExtended Trading$20.42 0.00 (-0.02%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAX vs. RYTM, IMVT, CNTA, COGT, and SRRKShould you buy Bicara Therapeutics stock or one of its competitors? MarketBeat compares Bicara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicara Therapeutics include Rhythm Pharmaceuticals (RYTM), Immunovant (IMVT), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. BCAX vs. RYTMBCAX vs. IMVTBCAX vs. CNTABCAX vs. COGTBCAX vs. SRRKHow does Bicara Therapeutics compare to Rhythm Pharmaceuticals?Rhythm Pharmaceuticals (NASDAQ:RYTM) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk. Which has preferable valuation and earnings, RYTM or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$217.17M28.60-$196.54M-$3.13N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Is RYTM or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Bicara Therapeutics' return on equity of -35.89% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-93.33% -203.25% -44.99% Bicara Therapeutics N/A -35.89%-33.78% Do analysts rate RYTM or BCAX? Rhythm Pharmaceuticals presently has a consensus price target of $131.81, indicating a potential upside of 45.42%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 48.18%. Given Bicara Therapeutics' higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.84Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Does the media favor RYTM or BCAX? In the previous week, Bicara Therapeutics had 9 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 10 mentions for Bicara Therapeutics and 1 mentions for Rhythm Pharmaceuticals. Bicara Therapeutics' average media sentiment score of -0.03 beat Rhythm Pharmaceuticals' score of -0.39 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, RYTM or BCAX? Rhythm Pharmaceuticals has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the broader market. SummaryBicara Therapeutics beats Rhythm Pharmaceuticals on 9 of the 13 factors compared between the two stocks.How does Bicara Therapeutics compare to Immunovant?Immunovant (NASDAQ:IMVT) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings. Which has better earnings & valuation, IMVT or BCAX? Immunovant is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.69N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Is IMVT or BCAX more profitable? Bicara Therapeutics' return on equity of -35.89% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -63.17% -58.01% Bicara Therapeutics N/A -35.89%-33.78% Do institutionals and insiders hold more shares of IMVT or BCAX? 47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer IMVT or BCAX? Immunovant presently has a consensus target price of $32.44, suggesting a potential downside of 8.76%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 48.18%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Does the media refer more to IMVT or BCAX? In the previous week, Immunovant had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for Immunovant and 10 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of -0.03 beat Immunovant's score of -1.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, IMVT or BCAX? Immunovant has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, meaning that its stock price is 157% less volatile than the broader market. SummaryBicara Therapeutics beats Immunovant on 10 of the 14 factors compared between the two stocks.How does Bicara Therapeutics compare to Centessa Pharmaceuticals?Centessa Pharmaceuticals (NASDAQ:CNTA) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Which has better earnings and valuation, CNTA or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$15M395.46-$197.53M-$1.79N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Do analysts recommend CNTA or BCAX? Centessa Pharmaceuticals currently has a consensus price target of $40.70, indicating a potential upside of 2.39%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 48.18%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Does the media refer more to CNTA or BCAX? In the previous week, Bicara Therapeutics had 10 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for Bicara Therapeutics and 0 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.03 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Centessa Pharmaceuticals Neutral Bicara Therapeutics Neutral Which has more risk & volatility, CNTA or BCAX? Centessa Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the broader market. Is CNTA or BCAX more profitable? Bicara Therapeutics' return on equity of -35.89% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -60.37% -44.17% Bicara Therapeutics N/A -35.89%-33.78% Do institutionals & insiders have more ownership in CNTA or BCAX? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryBicara Therapeutics beats Centessa Pharmaceuticals on 10 of the 15 factors compared between the two stocks.How does Bicara Therapeutics compare to Cogent Biosciences?Cogent Biosciences (NASDAQ:COGT) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Is COGT or BCAX more profitable? Bicara Therapeutics' return on equity of -35.89% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -104.27% -54.64% Bicara Therapeutics N/A -35.89%-33.78% Do analysts prefer COGT or BCAX? Cogent Biosciences currently has a consensus target price of $43.73, suggesting a potential upside of 32.83%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 48.18%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Does the media prefer COGT or BCAX? In the previous week, Bicara Therapeutics had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Bicara Therapeutics and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.03 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cogent Biosciences Neutral Bicara Therapeutics Neutral Which has better valuation and earnings, COGT or BCAX? Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$328.94M-$2.17N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Which has more risk & volatility, COGT or BCAX? Cogent Biosciences has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the broader market. SummaryBicara Therapeutics beats Cogent Biosciences on 6 of the 11 factors compared between the two stocks.How does Bicara Therapeutics compare to Scholar Rock?Bicara Therapeutics (NASDAQ:BCAX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Does the media favor BCAX or SRRK? In the previous week, Bicara Therapeutics had 3 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Bicara Therapeutics and 7 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.59 beat Bicara Therapeutics' score of -0.03 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Scholar Rock 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, BCAX or SRRK? Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$137.95M-$2.78N/AScholar RockN/AN/A-$377.94M-$3.59N/A Do insiders and institutionals have more ownership in BCAX or SRRK? 91.1% of Scholar Rock shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend BCAX or SRRK? Bicara Therapeutics currently has a consensus target price of $30.27, indicating a potential upside of 48.18%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 15.75%. Given Bicara Therapeutics' higher probable upside, research analysts plainly believe Bicara Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 5 Strong Buy rating(s) 3.17 Is BCAX or SRRK more profitable? Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A -35.89% -33.78% Scholar Rock N/A -163.52%-96.67% Which has more volatility and risk, BCAX or SRRK? Bicara Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. SummaryBicara Therapeutics beats Scholar Rock on 8 of the 14 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition ExportMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$3.30B$6.28B$12.28BDividend YieldN/A2.34%2.80%5.32%P/E Ratio-7.3518.7320.7425.19Price / SalesN/A183.15510.5761.33Price / CashN/A124.5843.0954.25Price / Book2.616.819.906.95Net Income-$137.95M$24.18M$3.55B$335.25M7 Day Performance-2.58%-0.25%-0.30%-0.70%1 Month Performance-12.95%-4.58%-2.34%-0.90%1 Year Performance35.84%55.65%30.89%29.67% Bicara Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.0389 of 5 stars$20.43+2.0%$30.27+48.2%+31.7%$1.32BN/AN/A32News CoverageInsider TradeRYTMRhythm Pharmaceuticals2.3128 of 5 stars$91.31+4.5%$131.81+44.4%+42.4%$5.99B$189.76MN/A140IMVTImmunovant1.0262 of 5 stars$28.65-1.4%$32.44+13.2%+78.8%$5.91BN/AN/A120Trending NewsEarnings ReportGap UpCNTACentessa Pharmaceuticals1.5088 of 5 stars$39.61+0.1%$40.70+2.8%+223.8%$5.91B$15MN/A200COGTCogent Biosciences2.2503 of 5 stars$34.53+1.3%$43.73+26.6%+527.5%$5.83BN/AN/A80 Related Companies and Tools Related Companies RYTM Competitors IMVT Competitors CNTA Competitors COGT Competitors SRRK Competitors XENE Competitors GRFS Competitors APLS Competitors APGE Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
